uniQure N.V. (QURE) Stock Price & How to Invest
Last updated July 2026
Short answer
You can invest in uniQure (QURE) by buying shares or fractional shares at any major broker, or holding it inside a thematic gene-therapy or biotech basket. uniQure is a clinical-stage gene-therapy company whose value is dominated by one late-stage asset, AMT-130 for Huntington's disease, which is heading toward an FDA accelerated-approval submission, so it trades as a high-risk, event-driven biotech rather than a cash-flowing business.
QURE stock price
As of 2026-07-27, uniQure N.V. (QURE) last closed at $38.21, up 155.1% over the past year. Over the past 52 weeks it has traded between $9.03 and $70.59.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or uniQure N.V.'s investor relations page. Walnut is informational, not investment advice.
What does uniQure N.V. (QURE) do?
uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study. The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income.
The investment picture is that of a single-asset biotech. Product revenue is minimal (a few million dollars a quarter, mostly license and royalty income), and the company runs a large net loss funding R&D and commercial preparation. What matters is AMT-130: uniQure reached agreement with the FDA that its three-year data can support a Biologics License Application under the accelerated-approval pathway, with the submission planned for the third quarter of 2026 and a potential decision as early as mid-2027. Because Huntington's has no approved disease-modifying therapy and decades of prior failures, a first approval could be transformative, while a setback would remove most of the thesis. A cash balance of roughly $587 million funds operations into the second half of 2029, giving runway through the key regulatory events.
What's driving uniQure N.V. (QURE)?
1. AMT-130 accelerated-approval path.
The FDA has agreed that AMT-130's three-year Phase I/II data can serve as the primary basis for a BLA under the accelerated-approval pathway, and uniQure plans to submit in Q3 2026. AMT-130 carries RMAT, Breakthrough Therapy, and Fast Track designations, and Huntington's has no approved disease-modifying treatment, so a first-to-market gene therapy would define the company's value.
2. First-mover position in Huntington's.
Competing programs from Roche/Ionis, Wave, PTC, and others are either earlier stage or have stumbled, most notably Roche's tominersen, which failed to show meaningful clinical benefit. That leaves uniQure ahead of the field with the most advanced disease-modifying candidate and strong three-year efficacy data, at least for now.
3. Pipeline and platform optionality.
Beyond Huntington's, uniQure has early clinical programs in SOD1 ALS (AMT-162), refractory temporal-lobe epilepsy (AMT-260), and Fabry disease (AMT-191), plus royalties from the already-approved hemophilia B gene therapy Hemgenix, commercialized by CSL Behring. These provide additional shots on goal and some validation of the AAV platform.
4. Funded through key catalysts.
uniQure held roughly $587 million in cash, equivalents, and investments as of the first quarter of 2026, which management projects funds operations into the second half of 2029. That runway covers the planned BLA submission and a potential approval decision without an immediate need to raise capital under pressure.
What are the risks to uniQure N.V. (QURE)?
uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value. The accelerated-approval pathway still requires alignment with the FDA on a confirmatory study, and there is precedent for the agency demanding more evidence in neurology. The rest of the pipeline is early and unproven, so it offers limited support if the lead program falters. As a pre-profit company, uniQure burns tens of millions per quarter and will likely need to raise capital again, which can dilute shareholders, and the stock is highly volatile and prone to large swings around clinical and regulatory news. Competition in Huntington's is also intensifying as rival mechanisms advance.
How is uniQure N.V. (QURE) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see uniQure N.V.'s investor relations page or your broker.
- Revenue (Q1 2026): ~$3.6M (mostly license and royalty)
- Net loss (Q1 2026): ~$53.5M (~$0.85 per share)
- R&D expense (Q1 2026): ~$29M
- Cash and investments: ~$587M (into 2H 2029 runway)
- Share price: ~$39 (late July 2026)
- Market cap: ~$1.0-2.0B (moves sharply on news)
uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of its pipeline, chiefly AMT-130. Product revenue is minimal, with most of the small top line coming from Hemgenix royalties and license deals, while the company runs large losses funding development. The large cash balance relative to the market cap is a distinguishing feature, giving runway through the planned Q3 2026 BLA submission and beyond.
Who competes with uniQure N.V. (QURE)?
Huntington's disease programs
Roche/Ionis (tominersen ASO, which failed to show meaningful benefit), Wave Life Sciences (allele-selective ASO WVE-003), PTC Therapeutics (oral splicing modifier PTC518), Skyhawk, Vico, and Alnylam/Regeneron (RNAi ALN-HTT02) are all pursuing Huntington's, though most are earlier stage than AMT-130. They are the most direct threat to uniQure's first-mover position.
Gene-therapy and rare-disease biotechs
Companies such as Sarepta, uniQure's platform peers in AAV gene therapy, and other CNS-focused rare-disease developers compete for investor capital, manufacturing capacity, and clinical talent, and share the sector's regulatory and safety risks. Investor sentiment toward the whole gene-therapy space heavily influences QURE's valuation.
Large pharma partners and acquirers
Big pharmaceutical companies including CSL Behring (uniQure's Hemgenix partner) and others active in neurology and rare disease are both potential collaborators and potential acquirers, and their internal pipelines could eventually compete with uniQure's programs.
How to invest in uniQure N.V. (QURE)
There are three common ways to get QURE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so QURE sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where QURE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on uniQure N.V. (QURE)
uniQure is a binary, catalyst-driven gene-therapy stock whose price hinges far more on the regulatory fate of its Huntington's therapy AMT-130 than on current revenue, which means the outcome distribution is unusually wide in both directions.
More on uniQure N.V. (QURE)
Whether QURE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is QURE a buy?, and where the stock could go from here in the QURE stock forecast.
For income investors, whether QURE pays a dividend and how the payout looks is covered in does QURE pay a dividend?
Build a basket around QURE with Walnut
Use uniQure N.V. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does uniQure do?
+
uniQure is a clinical-stage biotech that develops one-time AAV gene therapies for serious genetic and central-nervous-system diseases. Its lead program is AMT-130 for Huntington's disease, and it has earlier programs in ALS, epilepsy, and Fabry disease, plus royalties from the approved hemophilia B therapy Hemgenix.
Why is QURE considered a high-risk stock?
+
Most of uniQure's value rests on a single asset, AMT-130. As a pre-profit biotech with minimal revenue and large losses, its share price swings sharply on clinical and regulatory news, so outcomes are unusually binary compared with a diversified, cash-flowing company.
What is AMT-130?
+
AMT-130 is uniQure's investigational one-time gene therapy for Huntington's disease, delivered surgically into the brain. In its Phase I/II study it met the primary endpoint at three years with roughly 75% slowing of disease progression versus external controls, and it holds RMAT, Breakthrough Therapy, and Fast Track designations.
When could AMT-130 be approved?
+
uniQure plans to submit a Biologics License Application to the FDA in the third quarter of 2026 under the accelerated-approval pathway, using its three-year data. With a rolling review, a decision could come as early as mid-2027, though timelines and outcomes are not guaranteed.
Does uniQure have any revenue?
+
Only a small amount. Q1 2026 revenue was about $3.6 million, mostly license income and royalties on Hemgenix, the hemophilia B gene therapy commercialized by CSL Behring. That is far below the company's operating costs, so it runs a substantial net loss.
Is uniQure at risk of running out of cash?
+
Not in the near term. uniQure reported roughly $587 million in cash and investments as of the first quarter of 2026, which it projects funds operations into the second half of 2029. That said, like most clinical-stage biotechs it may raise additional capital, which can dilute existing shareholders.
Who are uniQure's main competitors?
+
In Huntington's, rivals include Roche/Ionis (whose tominersen failed to show meaningful benefit), Wave Life Sciences, PTC Therapeutics, Skyhawk, Vico, and Alnylam/Regeneron, though most are earlier stage. More broadly it competes with other gene-therapy and rare-disease biotechs for capital and talent.
How can you invest in QURE?
+
QURE trades on the Nasdaq, so you can buy whole or fractional shares through any major broker, or gain indirect exposure through biotech or gene-therapy ETFs and thematic baskets that hold it. Walnut is not an investment adviser, and given the stock's volatility, position sizing and time horizon deserve careful thought.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with uniQure N.V.'s investor relations page or your broker before making investment decisions.